Finance

Lists
185750:KRX
Chong Kun Dang Pharmaceutical Corp
â‚©66,800.00
-1.76%
(-1,200.00) 1D
Sep 11, 3:30:15 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 185750...
Open
â‚©66,700
High
â‚©67,100
Low
â‚©66,200
Mkt. cap
922.03B
Avg. vol.
22.81K
Volume
0.00
Dividend
0.75%
Quarterly dividend
â‚©125
Ex-dividend date
Dec 29, 2025
P/E ratio
11.05
52-wk high
â‚©98,100
52-wk low
â‚©63,000
EPS
â‚©6,047
Shares outstanding
13.80M
No. of employees
2K
Open
â‚©66,700
High
â‚©67,100
Low
â‚©66,200
Mkt. cap
922.03B
Avg. vol.
22.81K
Volume
0.00
Dividend
0.75%
Quarterly dividend
â‚©125
Ex-dividend date
Dec 29, 2025
P/E ratio
11.05
52-wk high
â‚©98,100
52-wk low
â‚©63,000
EPS
â‚©6,047
Shares outstanding
13.80M
No. of employees
2K
About Chong Kun Dang Pharmaceutical Corp
CEOYoung-Joo Kim
Employees2.17K
Founded1941
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
429.82B
426.78B
447.77B
478.47B
Cost of goods sold
293.70B
296.28B
323.78B
338.01B
Cost of revenue
293.70B
296.28B
323.78B
338.01B
Research and development expenses
41.01B
35.34B
35.06B
45.96B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
69.14B
66.74B
68.78B
70.53B
Operating expense
115.13B
107.01B
109.90B
121.85B
Total operating expenses
408.83B
403.30B
433.68B
459.85B
Operating income
20.99B
23.48B
14.09B
18.61B
Other non operating income
252.87M
363.50M
362.33M
-438.08M
EBT including unusual items
20.81B
24.82B
13.70B
17.53B
EBT excluding unusual items
20.90B
23.93B
13.95B
17.14B
Income tax expense
576.67M
-1.47B
1.08B
-2.89B
Effective tax rate
2.77%
-5.93%
7.90%
-16.51%
Other operating expenses
2.80B
2.73B
3.80B
2.82B
Net income
20.10B
26.55B
12.82B
19.99B
Net profit margin
4.68%
6.22%
2.86%
4.18%
Earnings per share
-
-
-
-
Interest and investment income
1.25B
1.91B
1.80B
1.95B
Interest expense
-1.19B
-1.81B
-2.28B
-2.64B
Net interest expenses
58.24M
97.72M
-478.19M
-686.60M
Depreciation and amortization charges
1.37B
1.33B
1.29B
1.37B
EBITDA
32.20B
34.88B
25.66B
30.21B
Gain or loss from assets sale
-25.05M
-515.84M
138.15M
8.00K
AI content may include mistakes. Learn more
Google apps